Mizuho raised the firm’s price target on Ideaya Biosciences (IDYA) to $44 from $43 and keeps an Outperform rating on the shares following the research and development day. The firm left impressed by Ideaya’s ability to execute. Mizuho increased its probability of success for Ideaya’s lead asset darovasertib in uveal melanoma to 70% from 60%.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IDYA:
- IDEAYA Biosciences: Promising Clinical Developments and Strategic Positioning Highlighted by Buy Rating
- Ideaya Biosciences price target raised to $38 from $36 at RBC Capital
- Promising Pipeline and Competitive Edge: IDEAYA Biosciences Receives Buy Rating from Analyst
- Ideaya should be bought on yesterday’s selloff, says Wells Fargo
- Ideaya Biosciences selloff on R&D day overdone, says Citi